Reports of Biochemistry
and Molecular Biology
Tue, Oct 15, 2024
[Archive]
Volume 11, Issue 1 (Vol.11 No.1 Apr 2022)
rbmb.net 2022, 11(1): 10-19 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Beiki S, Tavakkol-Afshari J, Shariati-Sarabi Z, Poursamimi J, Gowhari Shabgah A, Mohammadi M. A Significant Reduction in the Plasma Levels and Gene Expression of CCL2 in Patients with Osteoarthritis following Intervention with Krocina™. rbmb.net 2022; 11 (1) :10-19
URL: http://rbmb.net/article-1-794-en.html
URL: http://rbmb.net/article-1-794-en.html
Samaneh Beiki 
, Jalil Tavakkol-Afshari , Zhaleh Shariati-Sarabi , Javad Poursamimi , Arezoo Gowhari Shabgah , Mojgan Mohammadi *
, Jalil Tavakkol-Afshari , Zhaleh Shariati-Sarabi , Javad Poursamimi , Arezoo Gowhari Shabgah , Mojgan Mohammadi *
Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract: (2647 Views)
Background: inflammatory chemokines such as CCL2 and CCL5 are involved in the progress of osteoarthritis. Crocin with antioxidant and anti-inflammatory properties can reduce the symptoms of osteoarthritis (OA). This study was performed investigate the effect of Krocina™, on the gene expressions and plasma levels of CCL2 and CCL5 in OA patients.
Methods: The study included 35 patients that were randomized in the KrocinaTM and placebo groups. The intervention was Krocina™ 15 mg daily for four months. Clinical and paraclinical parameters were measured. CCL2 and CCL5 genes expression and plasma levels were determined using the SYBR Green
Real-Time RT-PCR and Enzyme-linked Immunosorbent Assay (ELISA) techniques.
Results: The C-reactive protein (CRP) value in the KrocinaTM group and the visual analogue scale (VAS) value in the KrocinaTM and placebo groups decreased significantly after the intervention. The gene expression of CCL2 in the KrocinaTM and placebo groups decreased significantly. On the contrary, the gene expression of CCL5 in the KrocinaTM and placebo groups increased significantly. Moreover, the plasma levels of CCL2 in the KrocinaTM and placebo groups decreased meaningfully. There was no difference regarding the plasma levels of CCL5 within the Krocina™ and placebo groups before and after the intervention in either of the groups.
Conclusions: Administration of Krocina™ reduced the clinical signs of inflammation and CRP and VAS value. Also, Krocina™ significantly decreased the plasma levels and gene expression of CCL2 in osteoarthritis patients.
Methods: The study included 35 patients that were randomized in the KrocinaTM and placebo groups. The intervention was Krocina™ 15 mg daily for four months. Clinical and paraclinical parameters were measured. CCL2 and CCL5 genes expression and plasma levels were determined using the SYBR Green
Real-Time RT-PCR and Enzyme-linked Immunosorbent Assay (ELISA) techniques.
Results: The C-reactive protein (CRP) value in the KrocinaTM group and the visual analogue scale (VAS) value in the KrocinaTM and placebo groups decreased significantly after the intervention. The gene expression of CCL2 in the KrocinaTM and placebo groups decreased significantly. On the contrary, the gene expression of CCL5 in the KrocinaTM and placebo groups increased significantly. Moreover, the plasma levels of CCL2 in the KrocinaTM and placebo groups decreased meaningfully. There was no difference regarding the plasma levels of CCL5 within the Krocina™ and placebo groups before and after the intervention in either of the groups.
Conclusions: Administration of Krocina™ reduced the clinical signs of inflammation and CRP and VAS value. Also, Krocina™ significantly decreased the plasma levels and gene expression of CCL2 in osteoarthritis patients.
Type of Article: Original Article |
Subject:
Immunology
Received: 2021/09/30 | Accepted: 2021/10/1 | Published: 2022/05/26
Received: 2021/09/30 | Accepted: 2021/10/1 | Published: 2022/05/26
References
1. Chen D, Shen J, Zhao W, Wang T, Han L, Hamilton JL, et al. Osteoarthritis: Toward a comprehensive understanding of pathological mechanism. Bone Res. 2017;5:16044. [DOI:10.1038/boneres.2016.44] [PMID] [PMCID]
2. Taruc-Uy RL, Lynch SA. Diagnosis and Treatment of Osteoarthritis. Prim Care. 2013;40(4):821-36. [DOI:10.1016/j.pop.2013.08.003] [PMID]
3. Robinson WH, Lepus CM, Wang Q, Raghu H, Mao R, Lindstrom T, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12(10):580-92. [DOI:10.1038/nrrheum.2016.136] [PMID] [PMCID]
4. Haringman JJ, Ludikhuize J, Tak PP. Chemokines in joint disease: The key to inflammation?. Ann Rheum Dis. 2004;63(10):1186-1194. [DOI:10.1136/ard.2004.020529] [PMID] [PMCID]
5. Vergunst CE, Van De Sande MGH, Lebre MC, Tak PP. The role of chemokines in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol. 2005;34(6):415-25. [DOI:10.1080/03009740500439159] [PMID]
6. Xu YK, Ke Y, Wang B, Lin JH. The role of MCP‑1‑CCR2 ligand‑receptor axis in chondrocyte degradation and disease progress in knee osteoarthritis. Biol Res. 2015;48:64. [DOI:10.1186/s40659-015-0057-0] [PMID] [PMCID]
7. Nguyen LT, Sharma AR, Chakraborty C, Saibaba B, Ahn ME, Lee SS. Review of prospects of biological fluid biomarkers in osteoarthritis. Int J Mol Sci. 2017;18(3):601. [DOI:10.3390/ijms18030601] [PMID] [PMCID]
8. Miller RE, Tran PB, Das R, Ghoreishi-Haack N, Ren D, Miller RJ, et al. CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. Proc Natl Acad Sci U S A. 2012;109(50):20602-7. [DOI:10.1073/pnas.1209294110] [PMID] [PMCID]
9. Li L, Jiang BE. Serum and synovial fluid chemokine ligand 2/monocyte chemoattractant protein 1 concentrations correlates with symptomatic severity in patients with knee osteoarthritis. Ann Clin Biochem. 2015;52(2):276-82. [DOI:10.1177/0004563214545117] [PMID]
10. Hsu YH, Hsieh MS, Liang YC, Li CY, Sheu MT, Chou DT, et al. Production of the chemokine eotaxin-1 in osteoarthritis and its role in cartilage degradation. J Cell Biochem. 2004;93(5):929-39. [DOI:10.1002/jcb.20239] [PMID]
11. Guo-hua, Masuko-hongo K, Sakata M, Tsuruha J, Onuma H, Nakamura H, et al. The role of C-C chemokines and their receptors in osteoarthritis. Arthritis Rheum. 2001;44(5):1056-70.
https://doi.org/10.1002/1529-0131(200105)44:5<1056::AID-ANR186>3.0.CO;2-U [DOI:10.1002/1529-0131(200105)44:53.0.CO;2-U]
12. Alaaeddine N, Olee T, Hashimoto S, Creighton-Achermann L, Lotz M. Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis Rheum. 2001;44(7):1633-43.
https://doi.org/10.1002/1529-0131(200107)44:7<1633::AID-ART286>3.0.CO;2-Z [DOI:10.1002/1529-0131(200107)44:73.0.CO;2-Z]
13. Kim K, Lee H-Y, Lim S-J. Effects of increased standing balance on pain in patients with knee osteoarthritis. J Phys Ther Sci 2016;28(1):87-9. [DOI:10.1589/jpts.28.87] [PMID] [PMCID]
14. Lei M, Guo C, Hua L, Xue S, Yu D, Zhang C, et al. Crocin Attenuates Joint Pain and Muscle Dysfunction in Osteoarthritis Rat. Inflammation. 2017;40(6):2086-2093. [DOI:10.1007/s10753-017-0648-8] [PMID]
15. Mollazadeh H, Emami SA, Hosseinzadeh H. Razi's Al-Hawi and saffron (Crocus sativus): a review. Iran J Basic Med Sci. 2015;18(12):1153-1166.
16. Christodoulou E, Kadoglou NP, Kostomitsopoulos N, Valsami G. Saffron: A natural product with potential pharmaceutical applications. J Pharm Pharmacol. 2015;67(12):1634-49. [DOI:10.1111/jphp.12456] [PMID]
17. Alavizadeh SH, Hosseinzadeh H. Bioactivity assessment and toxicity of crocin: A comprehensive review. Food Chem Toxicol. 2014;64:65-80. [DOI:10.1016/j.fct.2013.11.016] [PMID]
18. Mohammadi A, Reza A, Karami B Mohammadi A, Reza A, Karami B, et al. Effect of Total Suspended Particulate Matter in the Air on Inflammation Factors and Apoptotic Markers in Diabetic Rats: The Protective Effect of Insulin and Crocin. Reports Biochem Mol Biol. 2021;10(2):334-345. [DOI:10.52547/rbmb.10.2.334] [PMID] [PMCID]
19. Ding Q, Zhong H, Qi Y, Cheng Y, Li W, Yan S, et al. Anti-arthritic effects of crocin in interleukin-1β-treated articular chondrocytes and cartilage in a rabbit osteoarthritic model. Inflamm Res 2013;62(1):17-25. [DOI:10.1007/s00011-012-0546-3] [PMID]
20. Poursamimi J, Shariati-Sarabi Z, Tavakkol-Afshari J, Mohajeri SA, Ghoryani M, Mohammadi M. Immunoregulatory Effects of Krocina TM, a Herbal Medicine Made of Crocin, on Osteoarthritis Patients: A Successful Clinical Trial in Iran. Iran J Allergy Asthma Immunol. 2020;19(3):253-263. [DOI:10.18502/ijaai.v19i3.3453]
21. Zhang H, Guan ZS, Guan SH, Yang K, Pan Y, Wu Y Y, et al. Identification of suitable candidate reference genes for gene expression analysis by RT-qPCR in peripheral blood mononuclear cells of CHB patients. Clin Lab. 2016;62(1-2):227-34. [DOI:10.7754/Clin.Lab.2015.150805]
22. Zhang W, Robertson J, Jones AC, Dieppe P A, Doherty M. The placebo effect and its determinants in osteoarthritis: Meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008;67(12):1716-23. [DOI:10.1136/ard.2008.092015] [PMID]
23. Wampold BE, Minami T, Tierney SC, Baskin TW, Bhati KS. The placebo is powerful: Estimating placebo effects in medicine and psychotherapy from randomized clinical trials. J Clin Psychol. 2005;61(7):835-54. [DOI:10.1002/jclp.20129] [PMID]
24. Li Y, Kakkar R, Wang J. In vivo and in vitro Approach to Anti-arthritic and Anti-inflammatory Effect of Crocetin by Alteration of Nuclear Factor-E2-Related Factor 2/hem Oxygenase (HO)-1 and NF-κB Expression. Front Pharmacol. 2018;9:1341. [DOI:10.3389/fphar.2018.01341] [PMID] [PMCID]
25. Mousavi B, Bathaie SZ, Fadai F, Ashtari Z, Ali Beigi N, Farhang S, et al. Safety evaluation of saffron stigma (Crocus sativus L.) aqueous extract and crocin in patients with schizophrenia. Avicenna J phytomedicine. 2015;5(5):413-9.
26. Mohamadpour AH, Ayati Z, Parizadeh M-R, Rajbai O, Hosseinzadeh H. Safety Evaluation of Crocin (a constituent of saffron) Tablets in Healthy Volunteers. Iran J Basic Med Sci. 2013;16(1):39-46.
27. Yorgun MA, Rashid K, Aslanidis A, Bresgen C, Dannhausen K, Langmann T. Crocin, a plant-derived carotenoid, modulates microglial reactivity. Biochem Biophys Rep. 2017;12:245-250. [DOI:10.1016/j.bbrep.2017.09.007] [PMID] [PMCID]
28. Yang R, Yang L, Shen X, Cheng W, Zhao B, Ali KH, et al. Suppression of NF-κB pathway by crocetin contributes to attenuation of lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol. 2012;674(2-3):391-6. [DOI:10.1016/j.ejphar.2011.08.029] [PMID]
29. Park JH, Lee KY, Park B, Yoon J. Suppression of Th2 chemokines by crocin via blocking of ERK-MAPK/NF-κB/STAT1 signalling pathways in TNF-α/IFN-γ-stimulated human epidermal keratinocytes. Exp Dermatol. 2015;24(8):634-6. [DOI:10.1111/exd.12726] [PMID]
30. Budd E. MicroRNAs in Osteoarthritis and Chondrogenesis [PhD thesis]. University of Southampton; 2016. 328p.
31. Sanati M.H, Sohan Forooshan Moghadam A, Ataei M, Arabzadeh Gh, Falahati K, Roshani F. Analysis of MicroRNA-18a Expression in Multiple Sclerosis Patients. Rep Biochem Mol Biol. 2020;8(4):429-437.
32. Jiang S de, Lu J, Deng Z han, Li Y sheng, Lei G hua. Long noncoding RNAs in osteoarthritis. Jt Bone Spine. 2017;84(5):553-556. [DOI:10.1016/j.jbspin.2016.09.006] [PMID]
33. Cen X, Huang XQ, Sun WT, Liu Q, Liu J. Long noncoding RNAs: A new regulatory code in osteoarthritis. Am J Transl Res. 2017;9(11):4747-4755.
34. Pradet-Balade B, Boulmé F, Beug H, Müllner EW, Garcia-Sanz JA. Translation control: Bridging the gap between genomics and proteomics?. Trends Biochem Sci. 2001;26(4):225-9. [DOI:10.1016/S0968-0004(00)01776-X]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
